Related references
Note: Only part of the references are listed.Irritable Bowel Symptoms in Inflammatory Bowel Disease: Diagnostic Uncertainty Meets Pathological Reality
Eamonn M. M. Quigley et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Fecal Markers: Calprotectin and Lactoferrin
Bincy P. Abraham et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2012)
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents
Pauliina Molander et al.
INFLAMMATORY BOWEL DISEASES (2012)
Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation
Judith E. Baars et al.
INFLAMMATORY BOWEL DISEASES (2012)
Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies
Ren Mao et al.
INFLAMMATORY BOWEL DISEASES (2012)
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
Geert D'Haens et al.
INFLAMMATORY BOWEL DISEASES (2012)
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis
M. De Vos et al.
JOURNAL OF CROHNS & COLITIS (2012)
Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease
Clas-Goran af Bjorkesten et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2012)
Evaluation of the Quantum Blue® rapid test for faecal calprotectin
Julie Wassell et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2012)
Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic Review
Jerome Filippi et al.
CURRENT DRUG TARGETS (2011)
Surgery for adult Crohn's disease: what is the actual risk?
Guillaume Bouguen et al.
GUT (2011)
Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease
Laurent Peyrin-Biroulet et al.
JOURNAL OF CROHNS & COLITIS (2011)
Update of fecal markers of inflammation in inflammatory bowel disease
Thomas A. Judd et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers
Petr Ricanek et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon
Michael Dam Jensen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI
Alain M. Schoepfer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
New MRI modalities for assessment of inflammatory bowel disease
Julian Panes et al.
GUT (2010)
Fecal Calprotectin Variability in Crohn's Disease
Bjorn Moum et al.
INFLAMMATORY BOWEL DISEASES (2010)
Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
Valle Garcia-Sanchez et al.
JOURNAL OF CROHNS & COLITIS (2010)
Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment
Taina Sipponen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2010)
Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis
Patrick F. van Rheenen et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Biological markers in inflammatory bowel disease: Practical consideration for clinicians
J. L. Mendoza et al.
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE (2009)
Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease
J. Rimola et al.
GUT (2009)
Fecal Calprotectin and Lactoferrin for the Prediction of Inflammatory Bowel Disease Relapse
Javier P. Gisbert et al.
INFLAMMATORY BOWEL DISEASES (2009)
Fecal Calprotectin and Lactoferrin as Noninvasive Markers of Pediatric Inflammatory Bowel Disease
Manohara Joishy et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2009)
Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-Elastase, CRP, and clinical indices
Jost Langhorst et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies
Alain M. Schoepfer et al.
INFLAMMATORY BOWEL DISEASES (2008)
Fecal Calprotectin, Lactoferrin, and Endoscopic Disease Activity in Monitoring Anti-TNF-alpha Therapy for Crohn's Disease
Taina Sipponen et al.
INFLAMMATORY BOWEL DISEASES (2008)
Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings
Toino Sipponen et al.
INFLAMMATORY BOWEL DISEASES (2008)
Fecal calprotectin: assessment of a rapid test
T. A. Vestergaard et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2008)
Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease
Michael Wagner et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome
T. Kaiser et al.
GUT (2007)
Fecal M2-pyruvate kinase (M2-PK): A novel marker of intestinal inflammation
Guy Chung-Faye et al.
INFLAMMATORY BOWEL DISEASES (2007)
Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation:: combination of parameters does not improve diagnostic accuracy of calprotectin
O. Schroeder et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy
Alexander C. von Roon et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Review article: biological activity markers in inflammatory bowel disease
D. Desai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Relationship between fecal lactoferrin and inflammatory bowel disease
Jun Dai et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2007)
Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease
Thomas R. Walker et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2007)
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease
CA Solem et al.
INFLAMMATORY BOWEL DISEASES (2005)
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease
F Costa et al.
GUT (2005)
How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)?
LGM Jorgensen et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2005)
C-reactive protein as a marker for inflammatory bowel disease
S Vermeire et al.
INFLAMMATORY BOWEL DISEASES (2004)
Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease
AG Roseth et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2004)
Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease
JA Tibble et al.
GASTROENTEROLOGY (2002)
A simple method for assessing intestinal inflammation in Crohn's disease
J Tibble et al.
GUT (2000)
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease
JA Tibble et al.
GASTROENTEROLOGY (2000)
Share Paper
